paclitaxel has been researched along with midostaurin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Gallucci, JC; Kinghorn, AD; Li, X; Ren, Y; Yu, J | 1 |
| Chung, WH; Han, K; Han, KT; Kim, M; Kim, Y; Lim, J; Park, IY | 1 |
| Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E | 1 |
3 other study(ies) available for paclitaxel and midostaurin
| Article | Year |
|---|---|
Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
Topics: Apoptosis; Asteraceae; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Sesquiterpenes | 2018 |
Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cytokines; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Spleen; Staurosporine; Xenograft Model Antitumor Assays | 2006 |
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors | 2012 |